Advanced Filters
noise

Berlin - Spandau, Germany Clinical Trials

A listing of Berlin - Spandau, Germany clinical trials actively recruiting patients volunteers.

Found 403 clinical trials

Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of HDV Infection

Finding biomarkers for stopping bulevirtide treatment of patients with hepatitis delta

18 years of age All Phase N/A
M Martin Wermke, MD

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T-cell genetically multi-edited and expressing a reversed, universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR …

18 years of age All Phase 1
S Sebastian Stintzing, MD

A Clinical Study of Arfolitixorin in Patients With mCRC

This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 60 people will participate in the study. There is already a standard therapy for treatment of colorectal cancer. …

18 years of age All Phase 1/2
D Dr. Valeria Rios Rodriguez

ToFAcitinib in Early Active Axial SpondyloarThritis:

This is a phase IV, multicentre, randomized, double-blind, placebo-controlled study designed to compare the efficacy and safety of tofacitinib versus placebo (on a background of an NSAID) over 16 weeks of treatment and 4 weeks of safety follow-up in subjects with early active axSpA and inadequate response to at least …

18 - 45 years of age All Phase 4
B Boehringer Ingelheim

A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3031185 in healthy male subjects following administration of multiple rising doses.

18 - 50 years of age Male Phase 1

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).

18 years of age All Phase 1/2

Cyclosporine In Takotsubo Syndrome

The goal of this clinical trial is to investigate the impact of repetitive acute Cyclosporine A (CsA) bolus therapy in patients suffering from TTS with an elevated risk of impaired outcome. The main question it aims to answer is whether CsA reduces myocardial injury (primary outcome). Participants will receive CsA …

18 years of age All Phase 2
F Franziska Hausmann, MD

Evaluation of Needs of Patients and Care-givers During and After Radiotherapy of Patients With Prostate Cancer

Exploratory qualitative survey to assess the needs of patients and their relatives during and after radiotherapy for prostate cancer and their attitudes and wishes regarding prehabilitation measures

18 years of age Male Phase N/A

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant …

18 - 45 years of age Female Phase 3

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

18 years of age All Phase 2

Simplify language using AI